TD Cowen Downgrades Cerevel Therapeutics Hldg to Market Perform, Announces $45 Price Target
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Joseph Thome has downgraded Cerevel Therapeutics Hldg (NASDAQ:CERE) from Outperform to Market Perform while setting a price target of $45.

December 08, 2023 | 10:13 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Cerevel Therapeutics was downgraded by TD Cowen from Outperform to Market Perform with a $45 price target.
Downgrades by analysts can lead to a negative perception among investors, potentially causing short-term price declines. The new price target may provide some support if it is above the current trading price, but the downgrade in rating is likely to have a more immediate negative impact.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100